Your Medical Device Is Ready.
Your Translation Isn't.
Here's Why That's a Problem.

You've spent months — maybe years — getting your medical device to market. The engineering is solid. The clinical data stacks up. The regulatory documentation is done.

And then, three weeks before submission, someone flags a terminology inconsistency in the Dutch IFU.

Not a mistranslation. Not a glaring error. A subtle inconsistency. The kind that looks minor on paper and costs you a month on the calendar.

This is the story we hear more than any other.

The Dirty Secret of Medical Device Localisation

Here's what nobody tells you at the start of a device development programme: translation is a regulatory activity, not an admin task.

Yet in most organisations, it's treated like one. It gets scheduled last. It gets handed to whoever is cheapest or fastest. It gets signed off by someone who doesn't speak the target language.

And then it gets rejected at review.

The EU MDR is explicit about this. Under Article 10(11), every device placed on the market must have documentation — IFUs, labels, technical files — in the official language of every member state where it's sold. That's not a suggestion. That's a market access requirement.

Miss it, or get it wrong, and you don't ship.

What "Wrong" Actually Looks Like

The translation errors that derail regulatory submissions are rarely dramatic. There's no Google Translate disaster, no comically wrong synonym. What actually causes problems is far more subtle — and far more common.

None of these are catastrophic in isolation. Together, they're a submission delay — and in some cases, a recall risk.

Why It Keeps Happening

The root cause is almost always structural. Translation gets commissioned after documents are finalised in the source language. At that point, timelines are tight, budgets are committed, and the focus is on delivery — not process.

But professional medical translation isn't a finishing step. It's a continuation of your quality process across every language you operate in. When it sits outside that process rather than within it, risk accumulates silently until it can't be ignored.

Add in the complexity of managing multiple language pairs simultaneously — each with its own regulatory expectations, terminology conventions, and formatting requirements — and you have a coordination challenge that general translation providers are simply not equipped to handle.

This is exactly why ISO 17100:2015 exists. It defines what a professional translation workflow looks like: qualified translators, independent review, documented processes, traceability. Not because it's bureaucratic box-ticking — because it works.

The Fix: Integration, Not Afterthought

The companies that get this right don't treat translation as a vendor relationship. They treat it as a regulatory partnership. In practice, that means:

• Starting earlier Bring your translation provider in before source documents are finalised — ideally at the point where terminology is being established. Build a glossary in English that will govern every language version. Catch ambiguities in the source before they become inconsistencies across twelve translations.
• Using a proper TEP workflow Translation, Editing, Proofreading — by three separate qualified linguists, none of whom are the same person wearing different hats. Our four-eyes principle exists because a translator cannot properly proofread their own work. In medical content, that's not a quality preference. It's a patient safety issue.
• Working with specialists, not generalists A linguist who has translated consumer electronics and happens to speak German is not qualified to handle an IFU for an invasive cardiac device. The terminology knowledge, the regulatory awareness, the clinical context — these come from experience in the field. Our medical and life sciences team works exclusively on healthcare and device content.
• Thinking about DTP from day one Text expansion is real. German runs 30% longer than English. Arabic runs right to left. Japanese doesn't hyphenate. If your label design doesn't account for this, your translated label will look different from your approved layout. Our document and DTP capability means we handle this end-to-end, not as an afterthought.
• Insisting on independent proofreading The final stage of any regulated translation should involve a linguist who has seen neither the source nor the translation before — reading the target document as a native speaker would. Fatigue and familiarity blind even excellent translators to their own errors.

A Word for Growing MedTech Companies

If you're a scaling medical device business — from first CE marking through to full EU roll-out — the regulatory burden you're carrying is identical to that of a multinational. The internal resource you have to manage it usually isn't.

That's where a specialist agency becomes not just useful but essential. You need a partner who understands what notified bodies look for, who knows the difference between a required regulatory term and a synonym, and who can scale with your documentation needs as your portfolio grows.

You don't need the cheapest translation. You need the one that doesn't come back to haunt you at submission.

The Bottom Line

When medical translation is integrated into your regulatory workflow from the start — with the right processes, the right specialists, and the right quality controls — submissions go smoother, revision cycles shrink, and your documentation holds up under scrutiny in every language it needs to.

If you're preparing multilingual documentation for MDR, IVDR, FDA, or any other regulatory framework, we'd love to talk.